History of multiple myeloma

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 3-23

  Kyle, Robert A ^a   Steensma, David P ^b  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BENCE JONES PROTEIN; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IRON; IRON DERIVATIVE; LENALIDOMIDE; MELPHALAN; OPIATE; PLACEBO; PREDNISONE; QUININE; RHUBARB EXTRACT; STEEL; THALIDOMIDE; URETHAN; VINCRISTINE;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN DETECTION; ANTIQUITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACKACHE; BEHCET DISEASE; BLOOD ANALYSIS; BONE FRAGILITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL FEATURE; CLINICAL PRACTICE; CONSTIPATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DYSPEPSIA; ELECTROPHORESIS; ERYTHEMA NODOSUM LEPROSUM; EVENING DOSAGE; FATIGUE; FEMUR FRACTURE; FETUS MALFORMATION; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HISTORY OF MEDICINE; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFLAMMATION; ISCHIALGIA; LEPROSY; LOADING DRUG DOSE; LOW BACK PAIN; META ANALYSIS (TOPIC); MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MORNING DOSAGE; MORNING SICKNESS; MOTOR DYSFUNCTION; MOUTH ULCER; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOMALACIA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEINURIA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLEROSIS; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WASTING SYNDROME; WEAKNESS; WHOLE BODY RADIATION;

ADRENAL CORTEX HORMONES; ALKYLATING AGENTS; BENCE JONES PROTEIN; BORONIC ACIDS; HISTORY, 19TH CENTURY; HISTORY, ANCIENT; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PREDNISONE; PROTEINURIA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; URETHANE;

EID: 79955601014     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_1     Document Type: Review

References (101)

1. Adams W (1872) Mollities ossium. Trans Pathol Soc Lond 23:186-187
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622 (Pubitemid 29269108)
3. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685
4. Alwall N (1947) Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet 2:388-389
5. Arinkin MI (1929) Die intravitale Untersuchungsmethodik des Knochenmarks. Folia Haematologie 38:233-240
6. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L (1987) High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869-872 (Pubitemid 18027425)
7. Bayne-Jones S, Wilson DW (1922) Immunological reactions of Bence Jones proteins. II. Differences between Bence Jones proteins from various sources. Bull Johns Hopkins Hosp 33:119-125
8. Bayrd ED, Heck FJ (1947) Multiple myeloma: a review of eighty-three proved cases. JAMA 133:147-157
9. Bence Jones H (1842) On gravel, calculus and gout; chiefly an application of Professor Liebig's physiology to the prevention and cure of these diseases. Taylor & Walton, London
10. Bence Jones H (1845) On the state in which the uric acid exists in the urine. R. Kinder, London
11. Bence Jones H (1847) Chemical pathology. Lancet 2:88-92
12. Bence Jones H (1848) On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond 138:55-62
13. Bence Jones H (1870) The life and letters of Faraday. J. B. Lippincott, Philadelphia
14. Bence Jones H (1929) An autobiography (with elucidations at later dates by his son, A.B. Bence Jones). Crusha & Sons, London (privately printed)
15. Bergsagel DE, Sprague CC, Austin C, Griffith KM (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21:87-99
16. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N (1958) Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 68:1128-1132
17. Cajal SR (1896) Estudios histologicos sobre los tumores epiteliales. Rev Trimest Microgr 1:83-111
18. Capasso LL (2005) Antiquity of cancer. Int J Cancer 113:2-13
19. Case DC Jr, Lee DJ III, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63:897-903
20. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085 (Pubitemid 24139577)
22. Day WH (1870) On the hypophosphites of iron, quinine, and strychnia in cases of general debility and nervous exhaustion. Trans Clin Soc Lond 3:1-7
23. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132 (Pubitemid 350146107)
24. Edelman GM, Gally JA (1962) The nature of Bence- Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. J Exp Med 116:207-227
25. Fefer A, Cheever MA, Greenberg PD (1986) Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 76:1269-1273 (Pubitemid 16093166)
26. Felter HW, Lloyd JU (1898-1900) King's American dispensatory. Ohio Valley Co, Cincinatti
27. Fleischer R (1880) Ueber das Vorkommen des sogenannten Bence Jones' schen Eiweisskorpers im normalen Knochenmark. Arch Pathol Anat Physiol Klin Med 80:842-849
28. Gahrton G, Tura S, Flesch M, Gratwohl A, Gravett P, Lucarelli G, Michallet M, Reiffers J, Ringden O, van Lint MT et al (1987) Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation. Blood 69:1262-1264 (Pubitemid 17080954)
29. Geschickter CF, Copeland MM (1928) Multiple myeloma. Arch Surg 16:807-863
30. Gestsdottir H, Eyjolfsson GI (2005) Myeloma in an archaeological skeleton from Hofstadir in Myvatnssveit. Laeknabladid 91:505-509
31. Grabar P, Williams CA (1953) Method permitting the combined study of the electrophoretic and the immunochemical properties of protein mixtures; application to blood serum. Biochim Biophys Acta 10:193-194
32. Grabstald H, Golbey R (1965) Clinical experiences with thalidomide in patients with cancer. Clin Pharmacol Ther 6:298-302
33. Hanna F (2005) Multiple myelomas in cats. J Feline Med Surg 7:275-287
34. Harley JB, Ramanan SV, Kim I, Thiagarajan PV, Chen JH, Gomez R, Koppel D, Hyde F, Gustke S, Krall J (1972) The cyclic use of multiple alkylating agents in multiple myeloma. W V Med J 68:1-3
35. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J (1979) Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 54:13-22 (Pubitemid 9228081)
36. Heller JD (1846) Die mikroscopisch-chemischpathologische untersuchung. Braumuller & Seidel, Vienna
37. Heremans JF (1959) Immunochemical studies on protein pathology. The immunoglobulin concept. Clin Chim Acta 4:639-646
38. Herrick JB, Hektoen L (1894) Myeloma: report of a case. Med News, Philadelphia 65:239-242
39. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076 (Pubitemid 32691956)
40. Holland JR, Hosley H, Scharlau C, Carbone PP, Frei E III, Brindley CO, Hall TC, Shnider BI, Gold GL, Lasagna L, Owens AH Jr, Miller SP (1966) A controlled trial of urethane treatment in multiple myeloma. Blood 27:328-342
41. Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA, Townsend SR, Harley JB, Hayes DM, Costa G, Holland JF (1967) Melphalan in multiple myeloma. Blood 30:74-83
42. Ishizaka K, Ishizaka T, Hornbrook MM (1966) Physicochemical properties of reaginic antibody. V. correlation of reaginic activity with gamma- E-globulin antibody. J Urol 97:840-853
43. Kahler O (1889) Zur symptomatologie des multiplen myeloms: Beobachtung von Albumosurie. Prager Med Wochenschr (Prague) 14:45
44. Korngold L, Lipari R (1956) Multiple myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple myeloma serum proteins. Cancer 9:262-272
45. Kühne (1883) Ueber Hemialbumose im Harn. Z Biol 19:209-227
46. Kunkel HG, Tiselius A (1951) Electrophoresis of proteins on filter paper. J Gen Physiol 35:89-118
47. Kyle RA (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64:814-826
48. Kyle RA (2000) Multiple myeloma: an odyssey of discovery. Br J Haematol 111:1035-1044
49. Kyle RA (2001) Henry Bence Jones - physician, chemist, scientist and biographer: a man for all seasons. Br J Haematol 115:13-18
50. Lee BJ, Sahakian G, Clarkson BD, Krakoff IH (1974) Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer 33:533-538
51. Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1:45
52. Lerner AB, Watson CJ (1947) Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci 214:410-415
53. Longsworth AB, Shedlovsky T, MacInnes DA (1939) Electrophoretic patterns of normal and pathological human blood serum and plasma. J Exp Med 70:399-413
54. Macintyre W (1850) Case of mollities and fragili tas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans 33:211-232
55. Marschalko T (1895) Ueber die sogenannten plasmazellen, ein Beitrage zur Kenntniss der Herkunft der entzundlichen infiltrationszellen. Arch Der matol Syph 30:241
56. Mass RE (1962) A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep 16:257-259
57. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG, Leone L (1985) Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol 13(5):239-243 (Pubitemid 15227884)
58. McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824 (Pubitemid 13013370)
59. Morse D, Dailey RC, Bunn J (1974) Prehistoric multiple myeloma. Bull New York Acad Med 50:447-458
60. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842
61. Nerlich AG, Rohrbach H, Bachmeier B, Zink A (2006) Malignant tumors in two ancient populations: an approach to historical tumor epidemiology. Oncol Rep 16:197-202
62. Nothnagel H (1893) Hofrath Otto Kahler. Wien Klin Wochenschr (Wien) 6:79-80
63. Obituary (1873). Henry Bence Jones, M.D., F.R.C.P., F.R.S. Med Times Gaz 1:505
64. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF (1965) Thalidomide (N-Phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 6:292-297
65. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348 (Pubitemid 28450035)
66. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427 (Pubitemid 35334752)
67. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R (1982) Identical twin marrow transplantation in multiple myeloma. Acta Haematol 68:215-223 (Pubitemid 12029142)
68. Perlzweig WA, Delrue G, Geschicter C (1928) Hyperproteinemia associated with multiple myelomas: report of an unusual case. JAMA 90:755-757
69. Peters GA, Horton BT (1941) Allergic purpura with special reference to hypersensitiveness to cold. Mayo Clin Proc 16:631-636
70. Putnam FW (1993) Henry Bence Jones: the best chemical doctor in London. Perspect Biol Med 36:565-579
71. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053 (Pubitemid 41775908)
72. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067 (Pubitemid 35217050)
73. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617 [see comment]
74. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben- Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
75. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC (2006) A randomized phase 2 study of lenali domide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464
76. Rosenbloom J (1919) An appreciation of Henry Bence Jones, M.D., F.R.S. (1814-1873). Ann Med Hist 2:262-264
77. Rosenfeld L (1987) Henry Bence Jones (1813- 1873): the best "chemical doctor" in London. Clin Chem 33:1687-1692
78. Rosenthal N, Vogel P (1938) Value of the sternal puncture in the diagnosis of multiple myeloma. Mt Sinai J Med 4:1001-1019
79. Rothschild BM, Hershkovitz I, Dutour O (1998) Clues potentially distinguishing lytic lesions of multiple myeloma from those of metastatic carcinoma. Am J Phys Anthropol 105:241-250 (Pubitemid 28110404)
80. Rowe DS, Fahey JL (1965) A new class of human immunoglobulins. I. A unique myeloma protein. J Exp Med 121:171-184
81. Salmon SE, Shadduck RK, Schilling A (1967) Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep 51:179-187
82. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571 [see comment] [erratum appears in N Engl J Med 3 Feb 2000; 342(5):364]
83. Solly S (1844) Remarks on the pathology of mollities ossium with cases. Med Chir Trans 27:435-461
84. Steensma DP, Kyle RA (2007) A history of the kidney in plasma cell disorders. Contrib Nephrol 153:5-24 (Pubitemid 44836012)
85. Steinbock T (1976) Paleopathological diagnosis and interpretation. CC Thomas, Springfield
86. Stephens JL (1994) Arrowroot - Maranta arundinacea L. In: Fact Sheet HS-542. A series of the Horticultural Sciences Department, Florida Cooperative Exten sion Service, Institute of Food and Agricultural Services, University of Florida, Gainsville
87. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257:491-496
88. Tiselius A (1937a) Electrophoresis of serum globulin. II. Electrophoretic analysis of normal and immune sera. Biochem J 31:1464-1477
89. Tiselius A (1937b) A new apparatus for electrophoretic analysis of colloidal mixtures. T Faraday Soc 33:524
90. Tiselius A, Kabat EA (1939) Electrophoretic study of immune sera and purified antibody preparation. J Exp Med 69:119-131
91. von Behring EA, Kisato S (1890) Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Theieren. Dtsch Med Wochenschr 49:1113-1114
92. Waldenstrom J (1960-1961) Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 56:211-231
93. Waldeyer W (1875) Ueber bindegewebszellen. Arch Microbiol Anat 11:176-194
94. Weber H (1867) Mollities ossium, doubtful whether carcinomatous or syphilitic. Trans Pathol Soc Lond 23:186-187
95. Weber FP (1898) General lymphadenomatosis of bones, one form of 'multiple myeloma'. J Pathol 5:59-64
96. Weber FP, Hutchinson R, Macleod JJR (1903) Multiple myeloma (myelomatosis), with Bence- Jones protein in the urine (myelopathic albumosuria of Bradshaw, Kahler's disease). Am J Med Sci 126:644-665
97. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142 (Pubitemid 350146108)
98. Wells C (1964) Two mediaeval cases of malignant disease. BMJ 1:1611-1612
99. Wintrobe MM, Buell MV (1933) Hyperproteinemia associated with multiple myeloma, with report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease. Bull Johns Hopkins Hosp 52:156-165
100. Wright JH (1900) A case of multiple myeloma. Trans Assoc Am Physician 15:137-147
101. Zink A, Rohrbach H, Szeimies U, Hagedorn HG, Haas CJ, Weyss C, Bachmeier B, Nerlich AG (1999) Malignant tumors in an ancient Egyptian population. Anticancer Res 19:4273-4277